 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Immunitor Inc. |
| Street 1: | 365 - 2906 West Broadway |
| Street 2: | |
| City: | Vancouver |
| Province: | |
| Post Code: | |
| Country: | Canada |
| Phone: | 360-566-2194 |
| Organization Email: | info@immunitor.com |
| Web Site: | http://www.immunitor.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| Immunitor develops, manufactures, and clinically validates immunotherapies and therapeutic vaccines for tuberculosis indication including MDR-TB and TB-HIV. Our published clinical trials indicate fast sputum clearance resulting from adjunct immunotherapy. Current focus is an oral M vaccae formulation in Phase 2b clinical trial as a therapeutic vaccine. So far 2 phase trials were conducted. Sputum clearance was seen within one month in about 85% of patients. | |
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 6 - 10 |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 6 - 10 |
| Number of volunteers who are directly involved with TB: | 6 - 10 |
| How did you hear about the Stop TB Partnership: | Stop TB communications |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Our primary geographic focus is on countries where TB is highly prevalent, several of which we are already present with our ongoing work. | |
Geographical Reach | |
| Which country is your headquarters located in: | Canada |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Canada China India Lesotho Mongolia Nigeria Philippines Russian Federation South Africa Thailand Ukraine United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: We are working to enhance DOTS by using assessing the efficacy and safety of adjunct immunotherapies in association with DOTS drugs. Drug-Resistant TB: Our immunotherapies have shown efficacy for drug-resistant TB. TB-HIV: Our immunotherapies have shown efficacy for TB-HIV treatment. New TB Drugs: Although immunotherapies are not usually classified as "drugs", their addition to approved drug combination therapies for TB will reduce treatment duration and enhance their efficacy. New TB Vaccines: To date, our V5 and V7 products have shown clinical efficacy and safety as treatment vaccines. Current focus is on V7, an oral formulation of M. vaccae. |
|
Declaration | |
| Declaration of interests: Immunitor personnel have stock ownership and are thus incentivized. | |
| Application date: | October 20, 2011 |
| Last updated: | July 29, 2013 |